L&G Energy Transition Commodities UCITS ETF
Limited financial coverage for ENTR.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
This UCITS Exchange Traded Fund is dedicated to providing exposure to the essential commodities driving the global transition to sustainable energy.
- IPO
- 2017
- HQ
- Dublin, IE
Get TickerSpark's AI analysis on ENTR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- 52W High
- $17.00
- 52W Low
- $10.71
- 50D MA
- $15.20
- 200D MA
- $14.61
- Beta
- 1.25
- RSI (14)
- 66
- Avg Volume
- 8.73K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Entropic reported Q3 revenue of $43.2 million and a $0.11 non-GAAP loss per share, while announcing a major refocus and restructuring aimed at reaching non-GAAP profitability in Q1 2015.· November 10, 2014
- Q3 revenue was $43.2 million, down 14% sequentially, with non-GAAP EPS of $(0.11) and non-GAAP gross margin of 59%.
- Management is exiting new set-top box SoC development and concentrating on core RF, analog/mixed signal, DSP, and connectivity products.
- The company plans to cut non-GAAP operating expense to $20 million to $21 million per quarter by Q1 2015 and targets non-GAAP profitability in Q1 2015.
- Cash and investments were about $107 million at September 30, and management expects about $100 million at the end of Q4.
- Existing SoC products will still be sold and supported, but one bundled SoC+MoCA design win was removed from the outlook due to customer roadmap changes.
Revenue in Q3 2014 was $43.2 million, down 14% from Q2 and in line with revised guidance. Non-GAAP gross margin was 59%, non-GAAP operating expense was $35.4 million, non-GAAP net loss was about $10 million, and non-GAAP loss per share was $0.11; GAAP net loss was about $28 million and GAAP loss per share was $0.31. Cash and investments at September 30 were approximately $107 million. For Q4, management guided to revenue of $42 million to $43 million, non-GAAP gross margin of 55% to 57%, non-GAAP operating expense of about $30 million, non-GAAP loss per share of $0.07, and cash and investments of about $100 million at quarter-end. Looking ahead to Q1 2015, management said revenue should be about $40 million, non-GAAP operating expense should fall to $20 million to $21 million, and the company is targeting non-GAAP profitability.
Ted Tewksbury said the company is narrowing its focus to its core strengths in RF, analog/mixed signal, and DSP, describing these as difficult-to-replicate capabilities that should support a return to profitability. He framed the restructuring as a way to accelerate profitability while still investing in differentiated connectivity products and preserving support for existing customers. His tone was cautious but constructive: disappointed in recent results, yet confident the refocus can create a more streamlined and valuable company.
Dave Lyle said Q3 revenue of $43.2 million was down 14% sequentially, gross margin was 59%, and non-GAAP operating expense came in at $35.4 million, about $1.1 million better than prior guidance due to additional savings and restructuring-related cost reductions. He noted cash and investments of about $107 million at September 30, a roughly $14 million sequential decline, including $2.8 million of share repurchases, $1.5 million of restructuring cash outlays, and about $8 million of cash used in operations. For Q4, he guided to $42 million to $43 million of revenue, 55% to 57% gross margin, about $30 million of non-GAAP opex, and a $0.07 non-GAAP loss per share, while also saying the new restructuring should lower quarterly non-GAAP opex to $20 million to $21 million by Q1 2015 and bring breakeven revenue down to about $40 million.
Analysts focused on why Entropic would keep any set-top box exposure after exiting new integrated SoC development, and management said existing products are already commercialized or in production, have customer programs underway, and could contribute revenue for three years or more. Questions also centered on whether the digital CSS transition and bundled SoC+MoCA design wins could offset declines elsewhere; management said digital CSS should start to matter in 2015 but become more meaningful in 2016, and that two bundled wins are expected to ramp in Q1 2015 while one other was dropped because a customer changed its device roadmap. Analysts pressed on competitive standing and scale, and management argued Entropic can compete through product innovation, features, and performance rather than size, while acknowledging the company lacked the scale to pursue the prior integrated roadmap.
The bull case from the call is that Entropic still has meaningful core technology in connectivity, and management believes it can monetize RF, analog, mixed-signal, and DSP expertise in a lower-cost structure. The company also sees multiple growth avenues mentioned on the call—discrete MoCA, Wi-Fi extension, digital CSS, broadband access, and adjacent markets—while expecting existing SoC revenue to continue for several years.
The main bear case is that Entropic is retreating from new set-top box SoC development because management no longer believes it has the scale or roadmap to compete effectively there. The company also acknowledged customer roadmap shifts, including the loss of one bundled design win tied to faster-than-expected 4K/Ultra HD changes, and said digital CSS and some newer growth areas may take time to become meaningful.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 0.0%
- Shares Outstanding
- 5.45M
- Float Shares
- 0
of shares held by institutions
1 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Marxe Austin W & Greenhouse David M | 3.60M | ▲ 333.50K |
| Alpine Partners Usvi, LLC | 13.46K | ▲ 13.46K |
| Wilmington Funds Management Corp | 11.34K | ▲ 11.34K |
| Ubs AG | 2.26K | ▲ 2.26K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 30, 15 | PADVAL UMESH | sell | 118,755 |
| Apr 30, 15 | BAILEY ROBERT L | sell | 58,268 |
| Apr 20, 15 | PADVAL UMESH | other | 15,974 |
| Apr 20, 15 | BAILEY ROBERT L | other | 15,974 |
| Apr 20, 15 | BAILEY ROBERT L | other | 15,974 |
| Oct 29, 14 | PADVAL UMESH | other | 1,228 |
| Oct 29, 14 | PADVAL UMESH | other | 1,228 |
| Oct 27, 14 | PADVAL UMESH | other | 46,464 |
| Oct 27, 14 | PADVAL UMESH | other | 46,464 |
| Jun 1, 14 | FARESE MICHAEL J. | other | 7,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ENTR coverage
Recent articles, reports, and earnings notes.
No research on ENTR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENTR report →Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
globenewswire.com · May 7
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
globenewswire.com · May 6
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
globenewswire.com · May 28
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
globenewswire.com · Mar 24
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
globenewswire.com · Feb 24
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
globenewswire.com · Feb 3
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
globenewswire.com · Jun 24
This Week in ETFs: 7 New ETFs Dwarfed by 11 Closures
etftrends.com · Feb 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.